rofecoxib has been researched along with Carcinoma, Hepatocellular in 6 studies
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To know whether octreotide combined with rofecoxib would enhance the inhibitory effect on proliferation of hepatocellular carcinoma (HCC) in vitro and in vivo." | 7.72 | [The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma]. ( Liu, CL; Tang, CW; Zhou, XC, 2003) |
| "To know whether octreotide combined with rofecoxib would enhance the inhibitory effect on proliferation of hepatocellular carcinoma (HCC) in vitro and in vivo." | 3.72 | [The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma]. ( Liu, CL; Tang, CW; Zhou, XC, 2003) |
| "Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging." | 2.84 | Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. ( Andreesen, R; Endlicher, E; Ghibelli, L; Hackl, C; Herr, W; Klebl, F; Reichle, A; Schulz, U; Vogelhuber, M; Walter, I; Wiedmann, K; Wiest, R, 2017) |
| " Patients were prospectively randomised to receive open-label octreotide 30 mg monthly alone (n = 39) or in combination with rofecoxib (up to 50 mg bid daily, n = 32) for a minimum of six months, or until death occurred." | 2.73 | Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. ( Malfertheiner, P; Röcken, C; Treiber, G; Wex, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walter, I | 1 |
| Schulz, U | 1 |
| Vogelhuber, M | 1 |
| Wiedmann, K | 1 |
| Endlicher, E | 1 |
| Klebl, F | 1 |
| Andreesen, R | 1 |
| Herr, W | 1 |
| Ghibelli, L | 1 |
| Hackl, C | 1 |
| Wiest, R | 1 |
| Reichle, A | 1 |
| Liu, CL | 1 |
| Tang, CW | 1 |
| Zhou, XC | 1 |
| Treiber, G | 2 |
| Wex, T | 2 |
| Röcken, C | 2 |
| Fostitsch, P | 1 |
| Malfertheiner, P | 2 |
| Song, HJ | 1 |
| Kim, YS | 2 |
| Han, CH | 1 |
| Jang, JY | 1 |
| Kim, JH | 1 |
| Cheon, YK | 1 |
| Moon, JH | 1 |
| Cho, YD | 1 |
| Shim, CS | 1 |
| Kwon, KH | 1 |
| Kim, BS | 1 |
| Shen, WD | 1 |
| Liu, PF | 1 |
3 trials available for rofecoxib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Topics: Administration, Metronomic; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2006 |
Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2007 |
3 other studies available for rofecoxib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
[The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma].
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Pro | 2003 |
[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celeco | 2006 |
[The effects of refecoxib on inhibiting the growth and inducing apoptosis of hepatocellular carcinoma cell lines HepG2 and human normal liver cell line QSG7701].
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line; Hep G2 Cells; Humans; Lactones; Sulfones | 2006 |